查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1654296

精準腫瘤學市場規模、佔有率、趨勢分析報告（依產品類型、癌症類型、最終用途、地區、細分預測），2025-2030 年

Precision Oncology Market Size, Share & Trends Analysis Report By Product Type (Diagnostics, Therapeutics), By Cancer Type (Breast Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer), By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

精準腫瘤學市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，到2030年全球精準腫瘤學市場規模預計將達到2019.6億美元，2025年至2030年的複合年成長率為8.05%。

精準腫瘤學是一個正在發展的領域，其市場產品專注於腫瘤的分子分析以識別基因變異。目前，該行業取得了巨大的成功，患者的反應率達到 95%，同時質量調整生存期也延長了。市場產品有可能改善醫院和診所的患者照護並做出更明智的決策。此外，全球癌症發生率的不斷上升、臨床試驗研究數量的不斷增加以及精準腫瘤診斷技術的快速應用也有望推動市場需求。

由於全球癌症患者的醫療保健範圍不斷擴大並帶來了獨特的挑戰，精準腫瘤學市場受到了 COVID-19 疫情的嚴重影響。而且，精準腫瘤診斷和治療的延遲對癌症患者的診斷和治療產生了重大影響。然而，在新冠疫情之後，精準腫瘤學能夠提供更好的治療效果並改善癌症患者的生活品質，因此市場需求正在迅速成長。

2022 年 1 月，OncXerna Therapeutics, Inc. 和 Exact Sciences Corp. 宣布達成協議，將 OncXerna 的 TME Panel化驗服務帶給美國患者。這是一個創新的基因表現評分，可以幫助識別對免疫療法和抗血管新生療法有反應的患者。該公司進一步補充說，它有信心透過其生物製藥合作夥伴為臨床醫生提供 Xerna TME Panel，既作為伴同性診斷，也透過其現有的精準腫瘤學團隊。

精準腫瘤學市場報告重點

  • 根據產品類型，由於針對特定基因突變的標靶治療的持續開發和核准，治療藥物部門在 2024 年佔據市場最大收入佔有率，為 71.3%。
  • 根據癌症類型，乳癌領域在 2024 年佔據市場最大收益佔有率，達 41.7%。
  • 根據最終用途，醫院和診斷部門佔據市場主導地位，2024 年的收益佔有率最大，為 46.8%。在醫院和診斷領域，精準腫瘤學產品正在全球範圍內引起越來越多的關注，因為它們專注於腫瘤的分子分析以識別基因變異。
  • 2024 年北美精準腫瘤學市場佔最大收益佔有率，為 44.0%。該市場的主導地位歸因於可實現個人化治療方法的先進診斷工具的日益普及。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. 精準腫瘤學市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 精準腫瘤學市場分析工具
    • 產業分析-波特五力分析
    • PESTEL 分析

第4章精準腫瘤學市場：產品類型評估與趨勢分析

  • 2024 年及 2030 年產品類型市場佔有率
  • 細分儀表板
  • 全球精準腫瘤學市場依產品類型展望
  • 2018 年至 2030 年市場規模、預測及趨勢分析
    • 診斷
    • 治療

第5章精準腫瘤學市場：癌症類型估計與趨勢分析

  • 2024 年和 2030 年各癌症類型的市場佔有率
  • 細分儀表板
  • 全球精準腫瘤學市場按癌症類型展望
  • 2018 年至 2030 年市場規模、預測及趨勢分析
    • 乳癌
    • 大腸直腸癌
    • 子宮頸癌
    • 攝護腺癌
    • 肺癌
    • 其他

6. 精準腫瘤學市場：最終用途估計與趨勢分析

  • 2024 年及 2030 年終端用途市場佔有率
  • 細分儀表板
  • 全球精準腫瘤學市場前景（依最終用途）
  • 2018 年至 2030 年市場規模、預測及趨勢分析
    • 醫院及診斷
    • 製藥和生物技術
    • 醫療保健資料公司

第7章精準腫瘤學市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2018 年至 2030 年市場規模及預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • Key company market share analysis, 2024
    • Thermo Fisher Scientific Inc.
    • Invitae Corporation
    • Qiagen NV
    • Illumina, Inc.
    • Laboratory Corporation of America Holding
    • Exact Sciences Corporation
    • Rain Oncology Inc.
    • Strata Oncology Inc.
    • Xilis, Inc.
    • Variantyx, Inc.
    • Bioserve
    • Relay Therapeutics
    • Acrivon Therapeutics
Product Code: GVR-4-68040-032-5

Precision Oncology Market Growth & Trends:

The global precision oncology market size is expected to reach USD 201.96 billion by 2030, registering a CAGR of 8.05% from 2025 to 2030, according to a new report by Grand View Research, Inc. Precision oncology is a growing field where the market products emphasize on molecular profiling of tumors to identify alterations in the gene. Currently, the industry has witnessed major success with a 95% response rate being observed in patients along with extended quality-adjusted life. The market products offer the potential for improved patient care and a better-informed decision-making experience in hospitals and clinics. Alternatively, the increasing prevalence of cancer across the globe, the rising number of clinical trial studies, and the rapid adoption of technology in precision oncology diagnostic is anticipated to boost the market demand.

Due to the COVID-19 pandemic, the precision oncology market had a huge impact as the pandemic exaggerated healthcare across the globe for people living with cancer, possessing a unique set of challenges. Besides, delayed diagnosis and therapeutics using precision oncology have affected cancer patient diagnosis and treatment to a major extent. However, post-COVID-19 pandemic, the market has gained rapid demand as precision oncology offers better therapeutic outcomes and improves the quality of patient life for cancer patients.

In January 2022, OncXerna Therapeutics, Inc. and Exact Sciences Corp. mentioned the agreement to introduce OncXerna's TME Panel lab services for patients in the U.S. It is an innovative gene expression score, which helps identify patients to respond to immunotherapies and anti-angiogenic. Further, the company added that it believes to provide clinician access to the Xerna TME Panel through biopharma partners as a companion diagnostic and existing precision oncology team.

Precision Oncology Market Report Highlights:

  • Based on product type, the therapeutics segment led the market with the largest revenue share of 71.3% in 2024, due to the increasing development and approval of targeted treatments tailored to specific genetic mutations.
  • Based on cancer type, the breast cancer segment led the market with the largest revenue share of 41.7% in 2024, attributed to increasing awareness for breast cancer screening, diagnosis, and surgical and radiation techniques.
  • Based on end-use, the hospitals and diagnostic segment led the market with the largest revenue share of 46.8% in 2024. In hospital and diagnostic, precision oncology products are garnering an increasing amount of interest worldwide as it emphases molecular profiling of tumors to identify alterations in the gene.
  • North America precision oncology market dominated with the largest revenue share of 44.0% in 2024. The market dominance can be attributed to the increasing availability of advanced diagnostic tools that enable personalized treatment approaches.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Cancer Type
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product type outlook
    • 2.2.2. Cancer type outlook
    • 2.2.3. End Use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Precision Oncology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Cancer
      • 3.2.1.2. Advancements in Genomics and Molecular Diagnostics:
      • 3.2.1.3. Supportive Government and Private Sector Initiatives
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Costs of Precision Oncology Therapies
      • 3.2.2.2. Limited Access to Advanced Diagnostic Technologies:
  • 3.3. Precision Oncology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Precision Oncology Market: Product Type Estimates & Trend Analysis

  • 4.1. Product Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Precision Oncology Market by Product Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Diagnostics
      • 4.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Therapeutics
      • 4.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Precision Oncology Market: Cancer Type Estimates & Trend Analysis

  • 5.1. Cancer Type Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Precision Oncology Market by Cancer Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Breast Cancer
      • 5.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Colorectal Cancer
      • 5.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Cervical Cancer
      • 5.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.4. Prostate Cancer
      • 5.4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.5. Lung Cancer
      • 5.4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Precision Oncology Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Precision Oncology Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospitals and Diagnostic
      • 6.4.1.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.2. Pharmaceutical and Biotechnology
      • 6.4.2.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.3. Healthcare Data Companies
      • 6.4.3.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Precision Oncology Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Target disease prevalence
      • 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. Mexico market estimates and forecasts, 2018 to 2030, (USD Million
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Target disease prevalence
      • 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Target disease prevalence
      • 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Target disease prevalence
      • 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Target disease prevalence
      • 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Target disease prevalence
      • 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. Target disease prevalence
      • 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Target disease prevalence
      • 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Target disease prevalence
      • 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. Target disease prevalence
      • 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Target disease prevalence
      • 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. Target disease prevalence
      • 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Target disease prevalence
      • 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company market share analysis, 2024
    • 8.3.2. Thermo Fisher Scientific Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Invitae Corporation
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Qiagen N.V.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Illumina, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Laboratory Corporation of America Holding
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Exact Sciences Corporation
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Rain Oncology Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Strata Oncology Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Xilis, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Variantyx, Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Bioserve
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Relay Therapeutics
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Acrivon Therapeutics
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives

List of Tables

  • Table. 1 List of Abbreviation
  • Table. 2 North America precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 3 North America precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 4 North America precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 5 U.S. precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 6 U.S. precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 7 U.S. precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 8 Canada precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 9 Canada precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 10 Canada precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 11 Mexico precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 12 Mexico precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 13 Mexico precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 14 Europe precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 15 Europe precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 16 Europe precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 17 UK precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 18 UK precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 19 UK precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 20 Germany precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 21 Germany precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 22 Germany precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 23 France precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 24 France precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 25 France precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 26 Italy precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 27 Italy precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 28 Italy precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 29 Spain precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 30 Spain precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 31 Spain precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 32 Denmark precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 33 Denmark precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 34 Denmark precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 35 Sweden precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 36 Sweden precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 37 Sweden precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 38 Norway precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 39 Norway precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 40 Norway precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 41 Asia Pacific precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 42 Asia Pacific precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 43 Asia Pacific precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 44 Japan precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 45 Japan precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 46 Japan precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 47 China precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 48 China precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 49 China precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 50 India precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 51 India precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 52 India precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 53 Australia precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 54 Australia precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 55 Australia precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 56 Thailand precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 57 Thailand precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 58 Thailand precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 59 South Korea precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 60 South Korea precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 61 South Korea precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 62 Latin America precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 63 Latin America precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 64 Latin America precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 65 Brazil precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 66 Brazil precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 67 Brazil precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 68 Argentina precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 69 Argentina precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 70 Argentina precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 71 Middle East & Africa precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 72 Middle East & Africa precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 73 Middle East & Africa precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 74 South Africa precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 75 South Africa precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 76 South Africa precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 77 Saudi Arabia precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 78 Saudi Arabia precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 79 Saudi Arabia precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 80 UAE precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 81 UAE precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 82 UAE precision oncology market, by end use, 2018 - 2030 (USD Million)
  • Table. 83 Kuwait precision oncology market, by product type, 2018 - 2030 (USD Million)
  • Table. 84 Kuwait precision oncology market, by cancer type, 2018 - 2030 (USD Million)
  • Table. 85 Kuwait precision oncology market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Precision Oncology: Market outlook
  • Fig. 9 Precision Oncology: Competitive Insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Precision Oncology Market driver impact
  • Fig. 15 Precision Oncology Market Restraint Impact
  • Fig. 16 Precision Oncology Market Strategic Initiatives Analysis
  • Fig. 17 Precision Oncology market: Product type movement analysis
  • Fig. 18 Precision Oncology market: Product type outlook and key takeaways
  • Fig. 19 Diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Precision Oncology market: Cancer type movement analysis
  • Fig. 22 Precision Oncology market: Cancer type outlook and key takeaways
  • Fig. 23 Breast Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Colorectal Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Cervical Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Prostate Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Lung Cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Precision Oncology market: End Use movement analysis
  • Fig. 30 Precision Oncology market: End Use outlook and key takeaways
  • Fig. 31 Hospitals & Diagnostic Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pharmaceutical & Biotechnology Companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Healthcare Data Companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 North America precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.K. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Norway precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Denmark precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 China precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Australia precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Thailand precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Korea precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa. precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait precision oncology market estimates and forecasts, 2018 - 2030 (USD Million)